Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism

被引:121
|
作者
Hauser, MA [1 ]
Li, YJ
Xu, H
Noureddine, MA
Shao, YS
Gullans, SR
Scherzer, CR
Jensen, RV
McLaurin, AC
Gibson, JR
Scott, BL
Jewett, RM
Stenger, JE
Schmechel, DE
Hulette, CM
Vance, JM
机构
[1] Duke Univ, Med Ctr 2903, Ctr Human Genet, Durham, NC 27710 USA
[2] Duke Univ, Morris K Udall Parkinson Dis Res Ctr Excellence, Durham, NC 27710 USA
[3] Duke Univ, Dept Pathol, Durham, NC 27710 USA
[4] Duke Univ, Dept Med, Durham, NC 27710 USA
[5] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02138 USA
[6] Harvard Univ, Sch Med, Brigham & Womens Hosp, Morris K Udall Parkinson Dis Res Ctr, Cambridge, MA 02138 USA
[7] Wesleyan Univ, Dept Phys, Middletown, CT USA
关键词
D O I
10.1001/archneur.62.6.917
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Parkinson disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra. Genes contributing to rare mendelian forms of PD have been identified, but the genes involved in the more common idiopathic PD are not well understood. Objectives: To identify genes important to PD pathogenesis using microarrays and to investigate their potential to aid in diagnosing parkinsonism. Design: Microarray expression analysis of postmortem substantia nigra tissue. Patients: Substantia nigra samples from 14 unrelated individuals were analyzed, including 6 with PD, 2 with progressive supranuclear palsy, 1 with frontotemporal dementia with parkinsonism, and 5 control subjects. Main Outcome Measures: Identification of genes significantly differentially expressed (P<.05) using Affymetrix U133A microarrays. Results: There were 142 genes that were significantly differentially expressed between PD cases and controls and 96 genes that were significantly differentially expressed between the combined progressive supranuclear palsy and frontotemporal dementia with parkinsonism cases and controls. The 12 genes common to all 3 disorders may be related to secondary effects. Hierarchical cluster analysis after exclusion of these 12 genes differentiated 4 of the 6 PD cases from progressive supranuclear palsy and frontotemporal dementia with parkinsonism. Conclusions: Four main molecular pathways are altered in PD substantia nigra: chaperones, ubiquitination, vesicle trafficking, and nuclear-encoded mitochondrial genes. These results correlate well with expression analyses performed in several PD animal models. Expression analyses have promising potential to aid in postmortem diagnostic evaluation of parkinsonism.
引用
收藏
页码:917 / 921
页数:5
相关论文
共 50 条
  • [31] PROGRESSIVE SUPRANUCLEAR PALSY AND DEMENTIA
    ESPINO, DV
    AMERICAN FAMILY PHYSICIAN, 1990, 41 (04) : 1111 - 1111
  • [32] Progressive supranuclear palsy: New disease or variant of postencephalitic parkinsonism?
    Brusa, A
    Stoehr, R
    Pramstaller, PP
    MOVEMENT DISORDERS, 2004, 19 (03) : 247 - 252
  • [33] Cognitive–behavioural features of progressive supranuclear palsy syndrome overlap with frontotemporal dementia
    Christopher Kobylecki
    Matthew Jones
    Jennifer C. Thompson
    Anna M. Richardson
    David Neary
    David M. A. Mann
    Julie S. Snowden
    Alexander Gerhard
    Journal of Neurology, 2015, 262 : 916 - 922
  • [34] Action and object naming in frontotemporal dementia, progressive supranuclear palsy, and corticobasal degeneration
    Cotelli, M.
    Borroni, B.
    Manenti, R.
    Alberici, A.
    Calabria, M.
    Agosti, C.
    Arevalo, A.
    Ginex, V.
    Ortelli, P.
    Binetti, G.
    Zanetti, O.
    Padovani, A.
    Cappa, S. F.
    NEUROPSYCHOLOGY, 2006, 20 (05) : 558 - 565
  • [35] Comparison of prognostic factors in progressive supranuclear palsy and frontotemporal dementia (Uzbeki trial)
    Muinjonov, B.
    Giyazitdinova, E.
    Rakhimbayeva, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 805 - 805
  • [36] Neuropsychological profile of corticobasal degeneration, progressive supranuclear palsy and frontotemporal dementia patients
    Carmona-Abellan, M. M.
    Riverol, M.
    Recio, M.
    Echeveste, B.
    Imaz, L.
    Luquin, R.
    MOVEMENT DISORDERS, 2017, 32
  • [37] Survival in Progressive Supranuclear Palsy (PSP) and Frontotemporal Dementia (FTD) with Tau Pathology
    Gauthier, Serge
    Lopez, Oscar
    Schwam, Elias
    Waldemar, Gunhild
    Jones, Roy
    Wilkinson, David
    Zhang, Richard
    Schindler, Rachel
    NEUROLOGY, 2009, 72 (11) : A301 - A302
  • [38] Social cognition assessment in progressive supranuclear palsy: The cognitive interface with frontotemporal dementia
    Resende, E. P. F.
    Caramelli, P.
    Cardoso, F. E. C.
    Guimaraes, H. C.
    Hornberger, M.
    Bertoux, M.
    Teixeira, A. L.
    Cruz de Souza, L.
    MOVEMENT DISORDERS, 2016, 31 : S446 - S446
  • [39] Comparison of the pattern of atrophy of the corpus callosum in frontotemporal dementia, progressive supranuclear palsy, and Alzheimer's disease
    Yamauchi, H
    Fukuyama, H
    Nagahama, Y
    Katsumi, Y
    Hayashi, T
    Oyanagi, C
    Konishi, J
    Shio, H
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 69 (05): : 623 - 629
  • [40] STRIATAL PHOSPHOPROTEINS IN PARKINSON DISEASE AND PROGRESSIVE SUPRANUCLEAR PALSY
    GIRAULT, JA
    RAISMANVOZARI, R
    AGID, Y
    GREENGARD, P
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (07) : 2493 - 2497